Bimekizumab versus Adalimumab in Plaque Psoriasis.
Richard B WarrenAndrew BlauveltJerry BagelKim A PappPaul YamauchiApril ArmstrongRichard G LangleyVeerle VanvoordenDirk De CuyperChristopher CioffiLuke PetersonNancy CrossKristian ReichPublished in: The New England journal of medicine (2021)
In this 56-week trial, bimekizumab was noninferior and superior to adalimumab through 16 weeks in reducing symptoms and signs of plaque psoriasis but was associated with a higher frequency of oral candidiasis and diarrhea. Longer and larger trials are required to determine the efficacy and safety of bimekizumab as compared with other agents in the treatment of plaque psoriasis. (Funded by UCB Pharma; BE SURE ClinicalTrials.gov number, NCT03412747.).
Keyphrases
- coronary artery disease
- rheumatoid arthritis
- juvenile idiopathic arthritis
- atopic dermatitis
- clinical trial
- study protocol
- hidradenitis suppurativa
- candida albicans
- randomized controlled trial
- phase iii
- phase ii
- sleep quality
- depressive symptoms
- combination therapy
- physical activity
- systemic lupus erythematosus
- placebo controlled
- preterm birth
- double blind